
Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his resignation following a mutual agreement with the board.
Fruergaard will remain with the pharmaceutical giant until it finds a successor to “support a smooth transition,” a press release confirmed on Friday.